LABORATORY DIAGNOSTICS OF CERVICAL CANCER

Karimova Aziza Anvarovna; Kurbonova Zumrad Chutbayevna; Nimatova Mohigul Ilhom Qizi; Kurbanova Gavkhar Chutbayevna

doi:10.61796/jmgcb.v2i1.1081

Authors

Karimova Aziza Anvarovna
karimova@gmail.com
Tashkent Medical Academy, Uzbekistan
Kurbonova Zumrad Chutbayevna Tashkent Medical Academy, Uzbekistan
Nimatova Mohigul Ilhom Qizi Tashkent Medical Academy, Uzbekistan
Kurbanova Gavkhar Chutbayevna Tashkent Medical Academy, Uzbekistan

Vol. 2 No. 1 (2025): Journal of Medical Genetics and Clinical Biology

Articles

January 15, 2025

Downloads

View Article

Abstract
How to Cite
Metrics
References
License

Objective: This study examines current laboratory diagnostic techniques for cervical cancer, focusing on their application in diverse healthcare settings, with the goal of improving early detection and management. Methods: The research explores various diagnostic methods, including Pap smears, HPV DNA testing, and visual inspection with acetic acid (VIA), alongside advancements such as liquid-based cytology, molecular biomarkers, and artificial intelligence (AI). Comparative analysis highlights their effectiveness, sensitivity, and suitability across resource-diverse contexts. Results: Findings reveal that co-testing with cytology and HPV DNA testing offers superior sensitivity, while molecular diagnostics and liquid biopsy show promise for precision medicine. AI-based tools enhance diagnostic efficiency, particularly in underserved regions. However, challenges in accessibility, cost, and expertise persist in low-resource settings. Novelty: This study underscores the transformative potential of emerging technologies like AI-assisted diagnostics and liquid biopsy, emphasizing their role in bridging healthcare disparities and supporting the World Health Organization’s goal of eliminating cervical cancer by 2030.

Aziza Anvarovna, K., Chutbayevna, K. Z., Ilhom Qizi, N. M., & Chutbayevna, K. G. (2025). LABORATORY DIAGNOSTICS OF CERVICAL CANCER. Journal of Medical Genetics and Clinical Biology, 2(1), 53–60. https://doi.org/10.61796/jmgcb.v2i1.1081

Download Citation

C. A. Burmeister et al., “Cervical cancer therapies: Current challenges and future perspectives,” Tumour Virus Res., vol. 13, no. February, 2022, doi: 10.1016/j.tvr.2022.200238.

P. E. Castle, M. H. Einstein, and V. V. Sahasrabuddhe, “Cervical cancer prevention and control in women living with human immunodeficiency virus,” CA. Cancer J. Clin., vol. 71, no. 6, pp. 505–526, 2021, doi: 10.3322/caac.21696.

S. J. Curry, T. Byers, and M. Hewitt, Fulfilling the Potential of Cancer Prevention and Early Detection. 2004. doi: 10.17226/10941.

A. Sagan, D. Mcdaid, S. Rajan, J. Farrington, and M. Mckee, “Policy Brief Screening,” World Heal. Organ., 2020, [Online]. Available: http://www.euro.who.int/en/about-us/partners/

H. Ahmadzadeh Sarhangi, D. Beigifard, E. Farmani, and H. Bolhasani, “Deep learning techniques for cervical cancer diagnosis based on pathology and colposcopy images,” Informatics Med. Unlocked, vol. 47, no. March, p. 101503, 2024, doi: 10.1016/j.imu.2024.101503.

S. Ramakrishnan, S. Partricia, and G. Mathan, “Overview of high-risk HPV’s 16 and 18 infected cervical cancer: Pathogenesis to prevention,” Biomed. Pharmacother., vol. 70, no. C, pp. 103–110, 2015, doi: 10.1016/j.biopha.2014.12.041.

D. R. Lowy, D. Solomon, A. Hildesheim, J. T. Schiller, and M. Schiffman, “Human papillomavirus infection and the primary and secondary prevention of cervical cancer,” Cancer, vol. 113, no. 7, pp. 1980–1993, 2008, doi: 10.1002/cncr.23704.

R. Faridi, A. Zahra, K. Khan, and M. Idrees, “Oncogenic potential of Human Papillomavirus ( HPV ) and its relation with cervical cancer,” Virol. J., vol. 8, no. 269, pp. 1–8, 2011.

X. Wang, X. Huang, and Y. Zhang, “Involvement of human papillomaviruses in cervical cancer,” Front. Microbiol., vol. 9, no. NOV, pp. 1–14, 2018, doi: 10.3389/fmicb.2018.02896.

D. Geetha, J. Sangeetha, M. L. Malar, and T. V. Kumar, “Comparison of Liquid-Based Cytology and Conventional Pap Smear for Cervical Cancer Screening: a Comprehensive Analysis of Specimen Adequacy, Diagnostic Accuracy, and Clinical Correlation,” Int J Acad Med Pharm, vol. 6, no. 3, pp. 658–663, 2022, doi: 10.47009/jamp.2024.6.3.134.

I. N. Mammas and D. A. Spandidos, “George N. Papanicolaou (1883-1962): Fifty years after the death of a great doctor, scientist and humanitarian,” J. B.U.ON., vol. 17, no. 1, pp. 180–184, 2012.

P. L. Sachan, M. Singh, M. L. Patel, and R. Sachan, “A Study on Cervical Cancer Screening Using Pap Smear Test and Clinical Correlation,” Asia‑Pacific J. Oncol. Nurs., vol. 5, no. 3, pp. 337–341, 2018, doi: 10.4103/apjon.apjon.

F. sadat Najib, M. Hashemi, Z. Shiravani, T. Poordast, S. Sharifi, and E. Askary, “Diagnostic Accuracy of Cervical Pap Smear and Colposcopy in Detecting Premalignant and Malignant Lesions of Cervix,” Indian J. Surg. Oncol., vol. 11, no. 3, pp. 453–458, 2020, doi: 10.1007/s13193-020-01118-2.

B. Strander, A. Andersson-Ellström, I. Milsom, T. Rådberg, and W. Ryd, “Liquid-based cytology versus conventional Papanicolaou smear in an organized screening program : a prospective randomized study.,” Cancer, vol. 111, no. 5, pp. 285–291, 2007, doi: 10.1002/cncr.22953.

J. Zhu et al., “A comparison of liquid-based cytology and Pap smear as a screening method for cervical cancer,” Oncol. Rep., vol. 18, no. 1, pp. 157–160, 2007, doi: 10.3892/or.18.1.157.

M. G. Dijkstra et al., “Primary hrHPV DNA testing in cervical cancer screening: How to manage screen-positive women? a POBASCAM trial substudy,” Cancer Epidemiol. Biomarkers Prev., vol. 23, no. 1, pp. 55–63, 2014, doi: 10.1158/1055-9965.EPI-13-0173.